Medical network - April 13, 2009 medicare catalog adjusted once gave rise to a number of big big varieties, such as entecavir, mouse nerve growth factor, rui shu cut statin, pursuant to the adr, butyl phthalide, etc. In view of the new medical insurance directory adjustment as a result, this paper selected high quality pharmaceutical enterprise of high quality varieties were analysed. Hospital according to the sample data, select 25 new medicare catalog product were analyzed, and the involved more than 60 pharmaceutical enterprises, domestic enterprises mainly involve shiyao, hengrui, hogan &hartson, qilu, citic jian, baida, sunny, guizhou bobchao, method, etc., foreign companies are novartis, astrazeneca, lilly, etc. 

 

Antitumor drugs 

 

The main products are pemetrexed, the treatment of imatinib,, more gentle than the star, ek for vitamin B6, compound cantharis acid sodium, his west coast. 

 

Hospital according to the sample data statistics, in 2016 is expected to pemetrexed sales of 1.13 billion yuan, a total of 12 companies, the top three in the enterprise, jiangsu howson accounted for 34.1%, 32.3% of qilu, eli lilly (20.4%); Imatinib sales of 1.13 billion yuan, a total of 4 companies, novartis (86.7%), he (9.9%, 3.2%, nolato, 0.2% zhengda shine; The treatment for sales of 320 million yuan, a total of 2 companies, respectively, astrazeneca and approved in December 2016, qilu pharmaceutical; More gentle than sales of 282 million yuan, a total of eight companies, the top three companies were shiyao accounted for 52.3%, Shanghai fudan Zhang Jiangzhan, changzhou Jin Yuan accounted for 38.2% and 8.5%; Ek for sales of 240 million yuan, for the exclusive beida pharmaceutical products; Compound cantharis acid sodium vitamin B6 sales of 164 million yuan, for guizhou bobchao exclusive pharmaceutical products; His west marina sales of 65.16 million yuan, a total of 6 companies, the top three companies were Pharmachemie accounted for 54.1%, accounted for 28.7% of the weather is fine, he accounted for 9.4%. 

 

The digestive system drugs 

 

The main products are parlour SiQiong, moxa oprah etc, DORA SiQiong. According to sample hospital data statistics, in 2016 is expected to palo SiQiong generated sales of 1.13 billion yuan, a total of 9 companies, qilu pharmaceutical (hainan) accounted for 44.8%, 22.4%, the weather is fine JiuYuan accounted for 17.1%, other six (15.7%); Ai oprah azole sales of 120 million yuan, to be the sole product; DORA SiQiong sales of 120 million yuan, for liaoning sea exclusive cisco products. 

 

The preparation and mental disorders of the nervous system 

 

The nervous system drugs main products are butyl phthalide, lyrica. Mental disorders drug use the main products are right the microphones set. Hospital according to the sample data statistics, in 2016 is expected to butyl phthalide sales of 680 million yuan, for shiyao exclusive products, among them, the capsule sales of 440 million yuan, injection, and sales of 240 million yuan. Pregabalin, sales of 42.67 million yuan, at present only two companies, Pfizer (87.0%), chongqing sai d accounted for 13.0%. Is expected in 2016 right beautiful mi set sales of 484 million yuan, a total of four companies, the top three companies were hengrui accounted for 90.5%, China accounted for 5.6%, China accounted for 3.7%. 

 

Anti-infective drugs 

 

The main products are for add ring element, tenofovir, ertapenem. According to sample hospital data statistics, in 2016 is expected to add ring for sales of 288 million yuan, a total of seven companies, the top three in the enterprise, wyeth (33.6%), at 25.5%, the sea is 19.5%; Tenofovir sales of 110 million yuan, a total of 2 companies, glaxo and chengdu times in November 2016, approved by the pharmaceutical industry; Ertapenem sales of 44.43 million yuan, for MSD exclusive products. 

 

Immune modulators 

 

The main products are restructuring Ⅱ type of tumor necrosis factor receptor - antibody fusion protein, polyethylene glycol (peg) recombinant human granulocyte stimulating factor. Hospital according to the sample data statistics, restructuring in 2016 is expected to Ⅱ type of tumor necrosis factor receptor antibody fusion protein - sales of 288 million yuan, a total of 3 companies, Shanghai citic countries national health accounts for 94.1%, Shanghai is the biological 5.8%, the sea is 0.1%; Polyethylene glycol (peg) of recombinant human granulocyte stimulating factor generated sales of around 110 million yuan, a total of 2 companies, shandong grand hectogram (shiyao) accounted for 72.0%, 28.0% of qilu. 

 

The cardiovascular system and medical treatment 

 

The main products are cutting horse statin, ogilvy & mather, levosimendan. Hospital according to the sample data statistics, in 2016 is expected to cut statin sales of 157 million yuan, a total of 5 companies, the top three is China resources double crane (75.1%), period (75.1%) among all nations, biochemical (5.4%; Ogilvy sand sales of 109 million yuan, a total of 4 companies, top three, respectively is daiichi sankyo (78.9%), Beijing Wan Sheng accounted for 15.3% (3.4%), Shanghai sym Levosimendan sales of 57.24 million yuan, a total of 2 companies, and more than 96.6% of qilu, chengdu holy accounted for 3.4%. 

 

In other areas 

 

Blood and hematopoietic system polysaccharide drug use the main products are iron, song, class; Have trey vasopressin medicine endocrine and metabolic regulation; Have not cloth company he medicine bones and muscles. 

 

Hospital according to the sample data statistics, in 2016 is expected to polysaccharide iron sales of 102 million yuan, a total of 2 companies, huai schwarz (55.1%), Qingdao (44.9%); , sales of 57.54 million yuan, for the tianjin medicine research institute of pharmaceutical products. Endocrine and metabolic regulation of drug use, trey vasopressin sales of 96.57 million yuan, a total of 2 companies, shenzhen squire (75.0%), hui ling (25%). Bones and muscles use the cloth he sales of 64.24 million yuan, a total of 3 companies, jiangsu wanbang 61.0%, hengrui 31.6%, hangzhou zhuyangxin pharmaceutical industry accounted for 7.3%. 

 

Or will reshape the future market 

 

High quality products can enter health insurance directory is necessary for the future fast volume, but not all varieties into health care can be a big variety. Enterprise products to become a big market variety, but also conform to the clinical pathway, with pharmacoeconomics advantage in a business and a strong academic marketing ability, etc. 

 

Throughout history, in the new medical insurance directory about half a year, has won the bid provinces advantage varieties started peatlands cycle, rapid growth of general need three to five years. However, a new method of payment will have a greater impact to the enterprise product. The future curative effect good big varieties will refactoring to the entire market.